Description:Ozagrel sodium is a synthetic compound primarily used as a thromboxane A2 receptor antagonist, which plays a role in inhibiting platelet aggregation and promoting vasodilation. It is classified as a non-steroidal anti-inflammatory drug (NSAID) and is often utilized in the treatment of conditions related to cardiovascular health, particularly in managing acute ischemic stroke and other thromboembolic disorders. The substance is characterized by its ability to selectively inhibit the action of thromboxane A2, a potent vasoconstrictor and platelet aggregator, thereby contributing to improved blood flow and reduced clot formation. Ozagrel sodium is typically administered intravenously and is known for its relatively rapid onset of action. Its pharmacokinetics involve metabolism primarily in the liver, with excretion occurring through the kidneys. As with any medication, potential side effects may include bleeding complications, gastrointestinal disturbances, and allergic reactions. Overall, Ozagrel sodium represents a significant therapeutic option in the management of thrombotic conditions, highlighting the importance of targeted pharmacological interventions in cardiovascular medicine.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.